Path EX
PATH EX: Pioneering sepsis treatment through proprietary technology that selectively captures and removes bacteria from blood.
Founded
2016PATH EX: Pioneering sepsis treatment through proprietary technology that selectively captures and removes bacteria from blood.
Founded with the mission to revolutionize sepsis treatment, PATH EX has developed proprietary technology aimed at selectively separating and capturing bacteria and toxins from human blood. Sepsis, a critical and often fatal condition, is the leading cause of death in intensive care units and imposes significant costs on healthcare systems. PATH EX offers an extracorporeal blood cleansing device that targets and removes pathogens, including multi-drug resistant bacteria and endotoxins, from circulating blood. Their market focus is on providing advanced therapeutic and diagnostic solutions for sepsis.
Notable affiliated individuals include experts in medical technology and healthcare innovation. The company has attracted significant attention from investors focused on life-saving medical advancements. PATH EX's key achievements include the development of their groundbreaking blood cleansing device and its potential to drastically reduce sepsis-related mortality rates. The overall impact of PATH EX lies in its innovative approach to treating sepsis, offering a promising alternative to traditional broad-spectrum antibiotics and potentially transforming critical care practices.
Companies similar to Path EX include Opsonix, ExThera Medical, Immutrix Therapeutics and CytoSorbents.
Path EX was founded in 2016.
Path EX's headquarters is located in Nashville, TN, US.
Path EX's most recent funding round was for $2.5M (USD) in June 2021.
As of Jun 30, 2021, Path EX has disclosed funding of $4.8M (USD). Undisclosed round amounts are excluded.
Path EX has 3 employees as of Feb 5, 2024.
CytoSorbents
cytosorbents.com
